These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17189031)

  • 1. Suboptimum use of FDA drug advisory committees.
    Tapley AL; Lurie P; Wolfe SM
    Lancet; 2006 Dec; 368(9554):2210. PubMed ID: 17189031
    [No Abstract]   [Full Text] [Related]  

  • 2. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.
    Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED;
    Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CancerScope: FDA Advisory Committee supports second HPV vaccine.
    Printz C
    Cancer; 2009 Nov; 115(22):5130. PubMed ID: 19890873
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA updates health information advisory on melamine contamination.
    Lang L
    Gastroenterology; 2008 Nov; 135(5):1441. PubMed ID: 18848834
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA advisory committee meeting outcomes.
    Smith JF; Townsend SA; Singh N; Ma P
    Nat Rev Drug Discov; 2012 Jun; 11(7):513-4. PubMed ID: 22743972
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA advisory panel voices persistent safety concerns.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):439. PubMed ID: 16595778
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA advisory committee approves Selzentry.
    AIDS Patient Care STDS; 2009 Nov; 23(11):987. PubMed ID: 19938371
    [No Abstract]   [Full Text] [Related]  

  • 8. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
    Lurie P
    MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
    [No Abstract]   [Full Text] [Related]  

  • 9. Advisory committees" critical to the FDA's product review process.
    Rados C
    FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199
    [No Abstract]   [Full Text] [Related]  

  • 10. Group says FDA, advisory panels show bias toward drug approvals.
    Vedantam S
    Washington Post; 2006 Aug; ():A13. PubMed ID: 16941783
    [No Abstract]   [Full Text] [Related]  

  • 11. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.
    Kesselheim AS; Avorn J
    JAMA; 2016 Dec; 316(22):2357-2358. PubMed ID: 27775756
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 13. The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAA.
    Morrato EH; Ling SB
    Med Care; 2012 Nov; 50(11):970-86. PubMed ID: 23047787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
    Rosen CJ
    N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
    [No Abstract]   [Full Text] [Related]  

  • 15. Revisiting financial conflicts of interest in FDA advisory committees.
    Pham-Kanter G
    Milbank Q; 2014 Sep; 92(3):446-70. PubMed ID: 25199895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA revamps committee conflict-of-interest rules.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Oct; 98(19):1354-5. PubMed ID: 17018777
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does seating location impact voting behavior on Food and Drug Administration advisory committees?
    Broniatowski DA; Magee CL
    Am J Ther; 2013; 20(5):502-6. PubMed ID: 21642834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transparency at the Food and Drug Administration.
    Asamoah AK; Sharfstein JM
    N Engl J Med; 2010 Jun; 362(25):2341-3. PubMed ID: 20484392
    [No Abstract]   [Full Text] [Related]  

  • 20. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.